论文部分内容阅读
目的:探讨子宫内膜异位症并不孕的原因及治疗方案的临床意义。方法:随机选取2007年6月至2012年8月就诊于我院的不孕症或疑似子宫内膜异位症(EMS)经检查确诊为EMS的患者216例,按照用药区别平均分为六组,分别为三苯氧胺组、米非司酮组、丹那唑组、诺雷德组、无效成分安慰剂组及两阶段复合治疗组,记录上述患者经治疗后随访1年内受孕率情况。结果:无效成分安慰剂组无疗效,各方面与其他组比较有明显差异(P<0.05),其余各组疗效相比无明显差异(P>0.05);三苯氧胺组与丹那唑组不良反应发生率高于其他组,比较有明显差异(P<0.05);两阶段复合治疗组的复发率最低,受孕率最高,除安慰剂组外其他组之间比较无明显差异(P>0.05)。结论:此次研究的药物治疗效果近似,但是副作用、复发率及受孕率具有差异,临床应根据患者具体情况施治。
Objective: To investigate the causes of endometriosis infertility and its clinical significance. Methods: A total of 216 patients with infertility or suspected endometriosis (EMS) who were diagnosed as EMS at our hospital from June 2007 to August 2012 were randomly selected and divided into six groups , Respectively, tamoxifen group, mifepristone group, danazol group, noreid group, placebo group of inactive ingredients and two-phase combination treatment group, record the above patients within 1 year follow-up of pregnancy rate. Results: There was no significant difference between the placebo group and the other groups (P <0.05), but there was no significant difference between the other groups (P> 0.05). The incidence of adverse reactions in the tamoxifen group and the danazol group (P <0.05). The two groups had the lowest recurrence rate and the highest conception rate, there was no significant difference among the other groups except placebo group (P> 0.05). Conclusion: The drug treatment effect of this study is similar, but the side effects, recurrence rate and pregnancy rate are different, the clinical treatment should be based on the specific circumstances of patients.